PHARMACEUTICAL OVERVIEW

Today’s Pharma CMO needs to understand the interdependence of payer, provider and pharmaceutical value chains. While chronic diseases are on the rise, concern over drug pricing threatens brands.

Companies need to develop products consumers are willing to pay for and doctors are willing to prescribe across shifting global healthcare markets.

KEY INDUSTRY PAIN POINTS

  • Managing multi-country licensing and launches
  • Need to develop pricing flexibility
  • Healthcare policy makers are dictating what drugs doctors can prescribe

“We engaged Protagonist to help us understand the social media space around C-sections”

Dr. Stephanie Teleki

Director of Evaluation and Impact,

California Health Care Foundation

ENERGIZE YOUR BRAND

Rising drug prices are a hot button issue with consumers and will only continue to be so as health care coverage costs and availability come under siege. Narrative Analytics helps Pharma companies repair brands tarnished by negative press.

WIN A NARRATIVE BATTLE

A global conversation about high drug prices, even mitigated by high R&D costs, damages individual brands and the industry as a whole. Turning the conversation toward the good health outcomes patients experience through Pharma research transforms the conversation in a positive way.

ACTIVATE TARGET AUDIENCE

Basing product development and marketing campaigns on outdated market research methods is the equivalent of dancing in the dark. Only Protagonist can measure the emotional strength of Pharma narratives in play and show which ones resonate best.

Download Solution Briefs

PHARMACEUTICAL CUSTOMER CASE STUDY

Protagonist helped Pfizer find positive narratives to leverage to repair a brand damaged by pricing issues.

How Can We Change The Volatile Public Debate About Pharmaceutical Pricing?

CHALLENGE:

Shift the conversations to be more productive

SOLUTION:

Protagonist surfaced narratives about pricing from the general public, policymakers, and healthcare providers to reveal the Pharma industry’s position around R&D costs did not resonate with the marketplace

VALUE:

Identified an opportunity to amplify an emerging narrative about the value of drugs to patients and the outcomes created

START YOUR HERO’S JOURNEY NOW

CONTACT US